Literature DB >> 29385573

Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.

Yu-Mei Tan1, Rachel R Worley2, Jeremy A Leonard3, Jeffrey W Fisher4.   

Abstract

The development and application of physiologically based pharmacokinetic (PBPK) models in chemical toxicology have grown steadily since their emergence in the 1980s. However, critical evaluation of PBPK models to support public health decision-making across federal agencies has thus far occurred for only a few environmental chemicals. In order to encourage decision-makers to embrace the critical role of PBPK modeling in risk assessment, several important challenges require immediate attention from the modeling community. The objective of this contemporary review is to highlight 3 of these challenges, including: (1) difficulties in recruiting peer reviewers with appropriate modeling expertise and experience; (2) lack of confidence in PBPK models for which no tissue/plasma concentration data exist for model evaluation; and (3) lack of transferability across modeling platforms. Several recommendations for addressing these 3 issues are provided to initiate dialog among members of the PBPK modeling community, as these issues must be overcome for the field of PBPK modeling to advance and for PBPK models to be more routinely applied in support of public health decision-making.

Entities:  

Mesh:

Year:  2018        PMID: 29385573      PMCID: PMC6084449          DOI: 10.1093/toxsci/kfy010

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  69 in total

Review 1.  Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.

Authors:  H M Jones; Y Chen; C Gibson; T Heimbach; N Parrott; S A Peters; J Snoeys; V V Upreti; M Zheng; S D Hall
Journal:  Clin Pharmacol Ther       Date:  2015-01-09       Impact factor: 6.875

2.  Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.

Authors:  R Leong; M L T Vieira; P Zhao; Y Mulugeta; C S Lee; S-M Huang; G J Burckart
Journal:  Clin Pharmacol Ther       Date:  2012-05       Impact factor: 6.875

3.  Modeling Pharmacokinetics.

Authors:  Frederic Y Bois; Céline Brochot
Journal:  Methods Mol Biol       Date:  2016

4.  Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.

Authors:  Marije Strikwold; Bert Spenkelink; Ruud A Woutersen; Ivonne M C M Rietjens; Ans Punt
Journal:  Toxicol Sci       Date:  2017-06-01       Impact factor: 4.849

5.  A global human health risk assessment for octamethylcyclotetrasiloxane (D4).

Authors:  Robinan Gentry; Allison Franzen; C Van Landingham; Tracy Greene; Kathy Plotzke
Journal:  Toxicol Lett       Date:  2017-05-15       Impact factor: 4.372

6.  Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards.

Authors:  Hisham El-Masri; Nicole Kleinstreuer; Ronald N Hines; Linda Adams; Tamara Tal; Kristin Isaacs; Barbara A Wetmore; Yu-Mei Tan
Journal:  Toxicol Sci       Date:  2016-05-04       Impact factor: 4.849

7.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride.

Authors:  M E Andersen; H J Clewell; M L Gargas; F A Smith; R H Reitz
Journal:  Toxicol Appl Pharmacol       Date:  1987-02       Impact factor: 4.219

Review 8.  Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants.

Authors:  Mathieu Valcke; Kannan Krishnan
Journal:  J Appl Toxicol       Date:  2013-09-13       Impact factor: 3.446

9.  Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.

Authors:  Takao Watanabe; Hiroyuki Kusuhara; Kazuya Maeda; Yoshihisa Shitara; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2008-11-10       Impact factor: 4.030

10.  Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation.

Authors:  Kevin McNally; Richard Cotton; John Cocker; Kate Jones; Mike Bartels; David Rick; Paul Price; George Loizou
Journal:  J Toxicol       Date:  2012-04-08
View more
  15 in total

1.  Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology.

Authors:  D Lansing Taylor; Albert Gough; Mark E Schurdak; Lawrence Vernetti; Chakra S Chennubhotla; Daniel Lefever; Fen Pei; James R Faeder; Timothy R Lezon; Andrew M Stern; Ivet Bahar
Journal:  Handb Exp Pharmacol       Date:  2019

Review 2.  Physiological parameter values for physiologically based pharmacokinetic models in food-producing animals. Part I: Cattle and swine.

Authors:  Zhoumeng Lin; Miao Li; Yu-Shin Wang; Lisa A Tell; Ronald E Baynes; Jennifer L Davis; Thomas W Vickroy; Jim E Riviere
Journal:  J Vet Pharmacol Ther       Date:  2020-04-08       Impact factor: 1.786

3.  Methods for evaluating variability in human health dose-response characterization.

Authors:  Daniel A Axelrad; R Woodrow Setzer; Thomas F Bateson; Michael DeVito; Rebecca C Dzubow; Julie W Fitzpatrick; Alicia M Frame; Karen A Hogan; Keith Houck; Michael Stewart
Journal:  Hum Ecol Risk Assess       Date:  2019-11-06       Impact factor: 5.190

4.  A Systematic Review of Published Physiologically-based Kinetic Models and an Assessment of their Chemical Space Coverage.

Authors:  Courtney V Thompson; James W Firman; Michael R Goldsmith; Christopher M Grulke; Yu-Mei Tan; Alicia Paini; Peter E Penson; Risa R Sayre; Steven Webb; Judith C Madden
Journal:  Altern Lab Anim       Date:  2021-11-26       Impact factor: 1.303

Review 5.  Pharmacometrics: The Already-Present Future of Precision Pharmacology.

Authors:  Lorena Cera Bandeira; Leonardo Pinto; Cláudia Martins Carneiro
Journal:  Ther Innov Regul Sci       Date:  2022-08-18       Impact factor: 1.337

6.  Predicting Nanoparticle Delivery to Tumors Using Machine Learning and Artificial Intelligence Approaches.

Authors:  Zhoumeng Lin; Wei-Chun Chou; Yi-Hsien Cheng; Chunla He; Nancy A Monteiro-Riviere; Jim E Riviere
Journal:  Int J Nanomedicine       Date:  2022-03-24

Review 7.  Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach.

Authors:  Emily J Cox; Dan-Dan Tian; John D Clarke; Allan E Rettie; Jashvant D Unadkat; Kenneth E Thummel; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 8.  PBPK model reporting template for chemical risk assessment applications.

Authors:  Yu-Mei Tan; Melissa Chan; Amechi Chukwudebe; Jeanne Domoradzki; Jeffrey Fisher; C Eric Hack; Paul Hinderliter; Kota Hirasawa; Jeremy Leonard; Annie Lumen; Alicia Paini; Hua Qian; Patricia Ruiz; John Wambaugh; Fagen Zhang; Michelle Embry
Journal:  Regul Toxicol Pharmacol       Date:  2020-06-02       Impact factor: 3.271

Review 9.  Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials.

Authors:  Wells Utembe; Harvey Clewell; Natasha Sanabria; Philip Doganis; Mary Gulumian
Journal:  Nanomaterials (Basel)       Date:  2020-06-29       Impact factor: 5.076

Review 10.  Bridging the Data Gap From in vitro Toxicity Testing to Chemical Safety Assessment Through Computational Modeling.

Authors:  Qiang Zhang; Jin Li; Alistair Middleton; Sudin Bhattacharya; Rory B Conolly
Journal:  Front Public Health       Date:  2018-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.